D.A. Davidson & CO. increased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 28.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 180,904 shares of the pharmaceutical company’s stock after buying an additional 40,205 shares during the period. D.A. Davidson & CO.’s holdings in GlaxoSmithKline PLC were worth $7,798,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in GSK. Smithfield Trust Co. increased its stake in GlaxoSmithKline PLC by 7.0% in the third quarter. Smithfield Trust Co. now owns 2,430 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 160 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of GlaxoSmithKline PLC by 36.9% in the third quarter. Tower Research Capital LLC TRC now owns 2,640 shares of the pharmaceutical company’s stock worth $114,000 after buying an additional 712 shares during the period. Physicians Financial Services Inc. boosted its position in shares of GlaxoSmithKline PLC by 25.9% in the third quarter. Physicians Financial Services Inc. now owns 2,691 shares of the pharmaceutical company’s stock worth $116,000 after buying an additional 553 shares during the period. Quadrant Capital Group LLC boosted its position in shares of GlaxoSmithKline PLC by 11.7% in the third quarter. Quadrant Capital Group LLC now owns 3,044 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 319 shares during the period. Finally, Signaturefd LLC boosted its position in shares of GlaxoSmithKline PLC by 25.2% in the second quarter. Signaturefd LLC now owns 3,020 shares of the pharmaceutical company’s stock worth $131,000 after buying an additional 607 shares during the period. 8.41% of the stock is currently owned by institutional investors and hedge funds.
Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.261% on Monday, hitting $40.175. 1,125,878 shares of the stock traded hands. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $45.58. The firm has a market cap of $97.79 billion, a P/E ratio of 86.584 and a beta of 0.94. The firm’s 50-day moving average is $39.09 and its 200 day moving average is $40.98.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 8th. The pharmaceutical company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.04. GlaxoSmithKline PLC had a return on equity of 100.68% and a net margin of 3.11%. Equities research analysts forecast that GlaxoSmithKline PLC will post $2.74 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 13th. Shareholders of record on Friday, February 24th will be paid a dividend of $0.571 per share. This represents a $2.28 annualized dividend and a yield of 5.67%. The ex-dividend date is Wednesday, February 22nd. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is 389.36%.
“D.A. Davidson & CO. Buys 40,205 Shares of GlaxoSmithKline PLC (GSK)” was originally reported by sleekmoney and is owned by of sleekmoney. If you are reading this piece on another domain, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this piece can be viewed at http://sleekmoney.com/d-a-davidson-co-buys-40205-shares-of-glaxosmithkline-plc-gsk/1658178.html.
GSK has been the subject of a number of research reports. Investec initiated coverage on shares of GlaxoSmithKline PLC in a report on Thursday, October 20th. They issued a “buy” rating for the company. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, October 26th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Tuesday, December 27th. Goldman Sachs Group, Inc. (The) restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, December 27th. Finally, Jefferies Group LLC restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, December 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Buy” and an average price target of $48.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/d-a-davidson-co-buys-40205-shares-of-glaxosmithkline-plc-gsk/1658178.html
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.